Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma

2016 ◽  
Vol 105 (4) ◽  
pp. 445-452 ◽  
Author(s):  
Kenshi Suzuki ◽  
Hiroshi Handa ◽  
Takaaki Chou ◽  
Kenichi Ishizawa ◽  
Takatoshi Takubo ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Japanese Patients ◽  
Phase 1 Study ◽  
Refractory Multiple Myeloma

Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study

2016 ◽  
Vol 105 (3) ◽  
pp. 326-334 ◽  
Author(s):  
Shinsuke Iida ◽  
Hirokazu Nagai ◽  
Gen Kinoshita ◽  
Masafumi Miyoshi ◽  
Michael Robbins ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Japanese Patients ◽  
Phase 1 Study ◽  
Refractory Multiple Myeloma

scholarly journals Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Blood ◽  
2013 ◽  
Vol 121 (11) ◽  
pp. 1961-1967 ◽  
Author(s):  
Paul G. Richardson ◽  
David Siegel ◽  
Rachid Baz ◽  
Susan L. Kelley ◽  
Nikhil C. Munshi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Safety And Efficacy ◽  
Refractory Multiple Myeloma ◽  
Key Points

Key Points Pomalidomide with/without dexamethasone has promising activity and manageable toxicity in relapsed and refractory multiple myeloma patients.

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma

2015 ◽  
Vol 101 (3) ◽  
pp. 286-294 ◽  
Author(s):  
Kenshi Suzuki ◽  
Michinori Ogura ◽  
Yu Abe ◽  
Tatsuya Suzuki ◽  
Kensei Tobinai ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibody ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Refractory Multiple Myeloma

scholarly journals Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study

2020 ◽  
Vol 61 (7) ◽  
pp. 1669-1677
Author(s):  
Michael Rosenzweig ◽  
Joycelynne Palmer ◽  
Ni-Chun Tsai ◽  
Tim Synold ◽  
Xiwei Wu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Refractory Multiple Myeloma

Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma

Leukemia ◽  
2020 ◽  
Vol 35 (1) ◽  
pp. 255-258 ◽  
Author(s):  
Hans C. Lee ◽  
Noopur S. Raje ◽  
Ola Landgren ◽  
Vijay V. Upreti ◽  
Jin Wang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Antibody Drug Conjugate ◽  
Phase 1 Study ◽  
Refractory Multiple Myeloma ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals PF623 PHASE 1/2 STUDY OF ISATUXIMAB MONOTHERAPY FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN JAPANESE PATIENTS

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 265 ◽  
Author(s):  
S. Iida ◽  
K. Sunami ◽  
M. Ri ◽  
M. Matsumoto ◽  
C. Shimazaki ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Japanese Patients ◽  
Refractory Multiple Myeloma

scholarly journals A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

2019 ◽  
Vol 9 (10) ◽  
Author(s):  
Hans C. Lee ◽  
Jatin J. Shah ◽  
Lei Feng ◽  
Elisabet E. Manasanch ◽  
Rebecca Lu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 1 ◽  
Phase 1 Study ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document